Tetrapyrroles and derivatives
Abcam (R,S)-CPP, NMDA antagonist, 50MG
MW 252.2 Da. Potent, competitive NMDA antagonist. See separate isomer (ab120159). Also available in simple stock solutions (ab146720) - add 1 ml of water to get an exact, ready-to-use concentration.
The product is subject to the following: Abcam Restricted Use Statement
eMolecules 42417-39-0 | 3-Aminodihydrofuran-2(3H)-one hydrochloride | MFCD27977179 | 1g
Ambeed | 5-Ethoxy-1H-indole-2-carboxylic acid | 250mg | 632809689 | A591873 | 93476-60-9 | MFCD02664445 | 205.213 | C11H11NO3
If you are unable to find the chemical you are looking for, make sure you are logged into your fishersci.com account and click on the following link:
eMolecules Building Block Tool<|a>
Abcam Rotigotine hydrochloride, Dopamine receptor agonist, 10MG
MW 351.93 g/mol, Purity >99%. Dopamine receptor agonist. High affinity for D₁, D₂ and D₃ receptors (Ki values are 83, 13 and 0.71 nM, respectively). Shows significant affinity at α₂B and 5-HT₁A receptors (Ki values are 27 and 30 nM, respectively). Exhibits anti-Parkinsonian and antidepressant activity.
The product is subject to the following: Abcam Restricted Use Statement
Abcam GR 127935 hydrochloride, 5-HT1B/1D receptor antagonist, 50MG
MW 534.06 g/mol, Purity >97%. Potent and selective 5-HT₁B/₁D receptor antagonist (pKi = 8.5 for both 5-HT₁D in rat and 5-HT₁D in guinea pig). 100-fold selectivity over 5-HT₁A, 5-HT₁E, and 5-HT₂C. Displays centrally mediated effects upon systemic administration.
The product is subject to the following: Abcam Restricted Use Statement
Abcam SB 216763, GSK3 inhibitor, 1MG
MW 371.2 Da, Purity >98%. Potent and selective GSK3 inhibitor (Ki= 9 nM for GSK-3α). Has little activity against 24 other protein kinases (IC₅₀ > 10 μM). Stimulates glycogen synthesis, gene transcription and is cardio- and neuroprotective.
The product is subject to the following: Abcam Restricted Use Statement
Abcam AR 231453, GPR119 agonist, 25MG
MW 505.5 Da, Purity >99%. Potent, selective G-protein coupled receptor 119 (GPR119) agonist (EC₅₀ = 0.68 nM). Enhances glucose-induced insulin release. Antidiabetic activity. Orally active in vivo.
The product is subject to the following: Abcam Restricted Use Statement
Abcam GM 6001, MMP inhibitor, 5MG
MW 388.5 Da, Purity >98%. Broad spectrum potent MMP inhibitor. Ki values are 0.4 (MMP-1), 0.5 (MMP-2), 27 (MMP-3), 0.1 (MMP-8), 0.2 (MMP-9), 13.4 (MMP-14) and 0.36 (MMP-26) nM. IC₅₀ value for MMP-7 is 3.7 nM. Pharmacologically active in vivo.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Nocodazole, Microtubule inhibitor, 5MG
MW 301.32 Da, Purity >98%. Microtubule inhibitor. Rapidly depolymerises microtubules in vivo and inhibits tubulin polymerisation in vitro. Inhibits mitosis. Also reduces stem cell pluripotency factors Oct 4 and Nanog.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Dorsomorphin (Compound C), AMP-kinase inhibitor, 10MG
MW 399.5 Da, Purity >99%. Potent, selective and reversible inhibitor of AMP-kinase (Ki = 109 nM). Inhibits AMPK activation induced by AICAR (ab120358) and metformin (ab120847). Selective inhibitor of bone morphogenetic protein (BMP) type I receptors (ALK2, ALK3 and ALK6). Does not affect ZAPK, SYK, PKCθ, PKA and JAK3. Cell-permeable. Also available in a water soluble form (Dorsomorphin dihydrochloride - ab144821).
The product is subject to the following: Abcam Restricted Use Statement
Abcam x E-991 dihydrochloride, KCNQ channel blocker; blocks M current, 50MG
MW 449.4 Da, Purity >99%. Potent and selective blocker of KCNQ voltage-gated potassium channels. Blocks M current. (IC₅₀ values are 0.98 μM (M-current), 0.71 μM (KCNQ 2), 0.75 μM (KCNQX 1), >100 μM (Kv1.2) and >43 μM (Kv4.3). Potent pulmonary vasoconstrictor. Cognitive enhancer following oral administration in vivo.
The product is subject to the following: Abcam Restricted Use Statement
Abcam AMD3100 octahydrochloride, C x CR4 antagonist, 50MG
MW 794.5 Da, Purity >99%. Plerixafor (hydrochloride) is a macrocyclic compound that acts as an irreversible antagonist against the binding of CXCR4 with its ligand, SDF-1 (CXCL12). It suppresses infection by HIV with an IC₅₀ value of 1-10 ng/ml with selectivity toward CXCR4-tropic virus. Plerixafor mobilizes hematopoietic stem and progenitor cells for transplant better than G-CSF alone. It also increases T-cell trafficking in the blood and spleen as well as the central nervous system. Plerixafor regulates the growth of primary and metastic breast cancer cells and inhibits dissemination of ovarian carcinoma cells.
The product is subject to the following: Abcam Restricted Use Statement
Abcam AMD3100 octahydrochloride, C x CR4 antagonist, 10MG
MW 794.5 Da, Purity >99%. Plerixafor (hydrochloride) is a macrocyclic compound that acts as an irreversible antagonist against the binding of CXCR4 with its ligand, SDF-1 (CXCL12). It suppresses infection by HIV with an IC₅₀ value of 1-10 ng/ml with selectivity toward CXCR4-tropic virus. Plerixafor mobilizes hematopoietic stem and progenitor cells for transplant better than G-CSF alone. It also increases T-cell trafficking in the blood and spleen as well as the central nervous system. Plerixafor regulates the growth of primary and metastic breast cancer cells and inhibits dissemination of ovarian carcinoma cells.
The product is subject to the following: Abcam Restricted Use Statement
Abcam ENMD-1068, protease-activated receptor 2 (PAR2) anatagonist, 5MG
MW 283.41 Da, Purity >99%. Selective protease-activated receptor 2 (PAR2) antagonist (IC₅₀ = 1.2 mM). Anti-inflamatory agent. Active in vivo and in vitro.
The product is subject to the following: Abcam Restricted Use Statement
Abcam QNZ, NF-kB inhibitor, 1MG
MW 358.4 Da, Purity >98%. Potent, selective NF-kB inhibitor (IC₅₀ = 11 nM). Inhibits LPS-induced TNFα production (IC₅₀ = 7 nM). Reduces edema in inflammation in vivo..
The product is subject to the following: Abcam Restricted Use Statement